Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention.

Literature DB >> 28152465

Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention.

Brian J Sherman¹, Nathaniel L Baker², Aimee L McRae-Clark³.

Abstract

Motivational enhancement therapy (MET) is efficacious in reducing cannabis use, yet benefits are generally short-lived. Oxytocin is a hypothalamic neuropeptide that promotes prosocial behaviors and plays a role in drug-related neuroadaptations; as such, oxytocin may enhance the effect of MET on cannabis outcomes. Cannabis dependent adults were randomized to receive MET plus oxytocin (n =8) or placebo (n =8). Participants receiving oxytocin showed reductions in amount of cannabis used daily and number of sessions per day. Participants receiving placebo did not evidence significant reductions. Powered clinical trials of oxytocin-enhanced MET for cannabis use disorder are warranted.

Entities: Chemical Disease Gene Species

Keywords: Cannabis; Oxytocin; Treatment

Mesh：

Substances：
Oxytocics
Oxytocin

Year: 2017 PMID： 28152465 PMCID： PMC5361569 DOI： 10.1016/j.psychres.2017.01.027

Source DB: PubMed Journal: Psychiatry Res ISSN： 0165-1781 Impact factor: 3.222

18 in total

Review 1. Effect size, confidence interval and statistical significance: a practical guide for biologists.

Authors: Shinichi Nakagawa; Innes C Cuthill
Journal: Biol Rev Camb Philos Soc Date: 2007-11

2. A two-week pilot study of intranasal oxytocin for cocaine-dependent individuals receiving methadone maintenance treatment for opioid use disorder.

Authors: Christopher S Stauffer; Vivek Musinipally; Angela Suen; Kara L Lynch; Brad Shapiro; Joshua D Woolley
Journal: Addict Res Theory Date: 2016-05-25

Review 3. Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date.

Authors: Mary R Lee; Matthew C H Rohn; Gianluigi Tanda; Lorenzo Leggio
Journal: CNS Drugs Date: 2016-02 Impact factor: 5.749

4. Oxytocin increases trust in humans.

Authors: Michael Kosfeld; Markus Heinrichs; Paul J Zak; Urs Fischbacher; Ernst Fehr
Journal: Nature Date: 2005-06-02 Impact factor: 49.962

Review 5. Breaking the loop: oxytocin as a potential treatment for drug addiction.

Authors: Iain S McGregor; Michael T Bowen
Journal: Horm Behav Date: 2011-12-14 Impact factor: 3.587

6. Anxiolytic-like effect of oxytocin in the simulated public speaking test.

Authors: Danielle C G de Oliveira; Antonio W Zuardi; Frederico G Graeff; Regina H C Queiroz; José A S Crippa
Journal: J Psychopharmacol Date: 2011-05-09 Impact factor: 4.153

Review 7. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384

8. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress.

Authors: Markus Heinrichs; Thomas Baumgartner; Clemens Kirschbaum; Ulrike Ehlert
Journal: Biol Psychiatry Date: 2003-12-15 Impact factor: 13.382

9. Chronic exposure to Delta9-tetrahydrocannabinol downregulates oxytocin and oxytocin-associated neurophysin in specific brain areas.

Authors: Elena Butovsky; Ana Juknat; Judith Elbaz; Maytal Shabat-Simon; Raya Eilam; Abraham Zangen; Miriam Altstein; Zvi Vogel
Journal: Mol Cell Neurosci Date: 2006-03-02 Impact factor: 4.314

Review 10. Treatment of Cannabis Use Disorder: Current Science and Future Outlook.

Authors: Brian J Sherman; Aimee L McRae-Clark
Journal: Pharmacotherapy Date: 2016-05 Impact factor: 4.705

12 in total

1. Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder.

Authors: Dustin C Lee; Nicolas J Schlienz; Erica N Peters; Robert H Dworkin; Dennis C Turk; Eric C Strain; Ryan Vandrey
Journal: Drug Alcohol Depend Date: 2018-11-15 Impact factor: 4.492

Review 10. Consideration of sex as a biological variable in the translation of pharmacotherapy for stress-associated drug seeking.

Authors: Erin L Martin; Elizabeth M Doncheck; Carmela M Reichel; Aimee L McRae-Clark
Journal: Neurobiol Stress Date: 2021-07-10

Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention.

Review 1. Effect size, confidence interval and statistical significance: a practical guide for biologists.

2. A two-week pilot study of intranasal oxytocin for cocaine-dependent individuals receiving methadone maintenance treatment for opioid use disorder.

Review 3. Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date.

4. Oxytocin increases trust in humans.

Review 5. Breaking the loop: oxytocin as a potential treatment for drug addiction.

6. Anxiolytic-like effect of oxytocin in the simulated public speaking test.

Review 7. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

8. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress.

9. Chronic exposure to Delta9-tetrahydrocannabinol downregulates oxytocin and oxytocin-associated neurophysin in specific brain areas.

Review 10. Treatment of Cannabis Use Disorder: Current Science and Future Outlook.

1. Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder.

2. The effect of oxytocin, gender, and ovarian hormones on stress reactivity in individuals with cocaine use disorder.

Review 3. The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.

4. Sex differences in stress reactivity after intranasal oxytocin in recreational cannabis users.

5. Intranasal Oxytocin Does Not Modulate Responses to Alcohol in Social Drinkers.

Review 6. Combinatorial approaches for treating neuropsychiatric social impairment.

Review 7. Protecting children and adolescents against the risks of vaping.

Review 8. La protection des enfants et des adolescents contre les risques du vapotage.

Review 9. Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis.

Review 10. Consideration of sex as a biological variable in the translation of pharmacotherapy for stress-associated drug seeking.